CoMind

Executive Summary

CoMind is a London-based digital health and neuroscience company founded in 2019 with the mission to redefine how the brain is measured and treated, aiming to optimize patient outcomes across the care continuum. By leveraging advanced neurotechnology, CoMind seeks to bridge the gap between current measurement limitations and clinical needs, positioning itself at the intersection of neuroscience and digital health. While the company operates in a promising sector with high unmet medical need, its stage and financial details remain undisclosed, indicating an early or pre-revenue phase. The lack of public pipeline information or funding history suggests a need for further due diligence, but the focus on brain measurement and treatment aligns with growing trends in personalized medicine and non-invasive neurotherapeutics.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Announcement60% success
• Q4 2026Key Partnership with NHS or Academic Institution40% success
• 2027First-in-Human Clinical Trial Results25% success